Company press releases
Released | Company | Title | Industry | Topic |
---|---|---|---|---|
17 Feb 2022 07:40 CET |
VISTIN PHARMA | Vistin Pharma ASA: Fourth quarter 2021 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
16 Feb 2022 15:45 CET |
VISTIN PHARMA | New interim CEO | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
08 Feb 2022 14:00 CET |
VISTIN PHARMA | Vistin Pharma ASA: Invitation to Q4 2021 conference call | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
14 Dec 2021 09:38 CET |
VISTIN PHARMA | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
29 Oct 2021 14:39 CEST |
VISTIN PHARMA | Vistin Pharma ASA: Mandatory notification of trade | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
29 Oct 2021 13:51 CEST |
VISTIN PHARMA | Vistin Pharma ASA: Disclosure of large shareholding | 20103015 Pharmaceuticals | Major shareholding notifications |
28 Oct 2021 07:45 CEST |
VISTIN PHARMA | Vistin Pharma ASA: Third quarter 2021 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
21 Oct 2021 12:00 CEST |
VISTIN PHARMA | Vistin Pharma ASA: Invitation to Q3 2021 conference call | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
14 Sep 2021 08:34 CEST |
VISTIN PHARMA | Mandatory notification of trade in Vistin Pharma ASA | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
19 Aug 2021 07:45 CEST |
VISTIN PHARMA | Vistin Pharma ASA: Second quarter and first half 2021 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
12 Aug 2021 13:00 CEST |
VISTIN PHARMA | Vistin Pharma ASA: Invitation to Q2 2021 conference call | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |